[ NeuroVia raises $14M in Series A ]

NeuroVia has raised $14 million in Series A funding.

Founded in 2013, NeuroVia  is committed to addressing unmet medical needs in neurological diseases with the primary goal to arrest the onset of devastating neurological deficits associated with X-ALD.

The funding will support the advance of the company’s lead candidate, NV1205, into a clinical proof-of-concept development program in X-linked adrenoleukodystrphy (X-ALD).

Funding  Series A
Founded  2013
Country  USA
City  San Francisco, California
Founder / CEO  Giovanni Ferrara
Deal Size  $14M
Investors  Sanofi-Genzyme BioVentures
 Novartis Venture Fund
 BioMed Ventures
 Enso Ventures
Previous Investors  /